Shanghai Kaibao Pharmaceutical (300039) - Total Assets

Latest as of September 2025: CN¥4.96 Billion CNY ≈ $725.53 Million USD

Based on the latest financial reports, Shanghai Kaibao Pharmaceutical (300039) holds total assets worth CN¥4.96 Billion CNY (≈ $725.53 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Shanghai Kaibao Pharmaceutical book value and equity for net asset value and shareholders' equity analysis.

Shanghai Kaibao Pharmaceutical - Total Assets Trend (2006–2024)

This chart illustrates how Shanghai Kaibao Pharmaceutical's total assets have evolved over time, based on quarterly financial data.

Shanghai Kaibao Pharmaceutical - Asset Composition Analysis

Current Asset Composition (December 2024)

Shanghai Kaibao Pharmaceutical's total assets of CN¥4.96 Billion consist of 53.5% current assets and 46.5% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	13.1%
Accounts Receivable	CN¥472.12 Million	10.5%
Inventory	CN¥187.85 Million	4.2%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥168.80 Million	3.7%
Goodwill	CN¥0.00	0.0%

Asset Composition Trend (2006–2024)

This chart illustrates how Shanghai Kaibao Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shanghai Kaibao Pharmaceutical market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Shanghai Kaibao Pharmaceutical's current assets represent 53.5% of total assets in 2024, a decrease from 70.3% in 2006.
Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, up from 5.3% in 2006.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 2006.
Asset Diversification: The largest asset category is accounts receivable at 10.5% of total assets.

Shanghai Kaibao Pharmaceutical Competitors by Total Assets

Key competitors of Shanghai Kaibao Pharmaceutical based on total assets are shown below.

Company	Country	Total Assets
Changchun High & New Technology Industries Group Inc SHE:000661	China	CN¥31.46 Billion
Yuhan Corp. KO:000100	Korea	₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd SHG:600535	China	CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	China	CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	China	CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	China	CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	China	CN¥6.74 Billion
Cronos Group Inc TO:CRON	Canada	CA$1.18 Billion

Shanghai Kaibao Pharmaceutical - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	12.39	6.36	9.34
Quick Ratio	11.29	5.77	8.54
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥2.05 Billion	CN¥1.70 Billion	CN¥1.98 Billion

Shanghai Kaibao Pharmaceutical - Advanced Valuation Insights

This section examines the relationship between Shanghai Kaibao Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.45
Latest Market Cap to Assets Ratio	0.20
Asset Growth Rate (YoY)	-1.3%
Total Assets	CN¥4.52 Billion
Market Capitalization	$884.70 Million USD

Valuation Analysis

Below Book Valuation: The market values Shanghai Kaibao Pharmaceutical's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Shanghai Kaibao Pharmaceutical's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Shanghai Kaibao Pharmaceutical (2006–2024)

The table below shows the annual total assets of Shanghai Kaibao Pharmaceutical from 2006 to 2024.

Year	Total Assets	Change
2024-12-31	CN¥4.52 Billion ≈ $661.19 Million	-1.34%
2023-12-31	CN¥4.58 Billion ≈ $670.15 Million	+7.52%
2022-12-31	CN¥4.26 Billion ≈ $623.27 Million	+26.92%
2021-12-31	CN¥3.36 Billion ≈ $491.06 Million	+16.63%
2020-12-31	CN¥2.88 Billion ≈ $421.04 Million	+1.22%
2019-12-31	CN¥2.84 Billion ≈ $415.95 Million	+3.46%
2018-12-31	CN¥2.75 Billion ≈ $402.03 Million	+2.53%
2017-12-31	CN¥2.68 Billion ≈ $392.13 Million	+6.01%
2016-12-31	CN¥2.53 Billion ≈ $369.91 Million	+4.17%
2015-12-31	CN¥2.43 Billion ≈ $355.10 Million	+14.61%
2014-12-31	CN¥2.12 Billion ≈ $309.84 Million	+19.57%
2013-12-31	CN¥1.77 Billion ≈ $259.13 Million	+13.43%
2012-12-31	CN¥1.56 Billion ≈ $228.44 Million	+7.48%
2011-12-31	CN¥1.45 Billion ≈ $212.53 Million	+5.98%
2010-12-31	CN¥1.37 Billion ≈ $200.53 Million	+1.86%
2009-12-31	CN¥1.35 Billion ≈ $196.87 Million	+485.27%
2008-12-31	CN¥229.88 Million ≈ $33.64 Million	+42.24%
2007-12-31	CN¥161.61 Million ≈ $23.65 Million	+48.22%
2006-12-31	CN¥109.03 Million ≈ $15.96 Million	--

About Shanghai Kaibao Pharmaceutical

SHE:300039 China Drug Manufacturers - Specialty & Generic

Market Cap

$884.70 Million

CN¥6.05 Billion CNY

Market Cap Rank

#9663 Global

#2705 in China

Share Price

CN¥5.78

Change (1 day)

-0.69%

52-Week Range

CN¥5.62 - CN¥6.96

All Time High

CN¥12.44